ORALLY DISINTEGRATING TABLET COMPRISING GLYCOPYRROLATE FOR TREATING SIALORRHEA
The invention provides an orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate for treating sialorrhea, as well as a kit comprising the orally disintegrating tablet, prescribing information, and a container. The invention also provides a method of treating sialorrhea in a patient comprising administering the orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate to the patient.
1 . An orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate.
2 . The orally disintegrating tablet of claim 1 , wherein the therapeutically effective amount of glycopyrrolate is from about 1 mg to about 10 mg.
3 . The orally disintegrating tablet of claim 2 , wherein the therapeutically effective amount of glycopyrrolate is from about 1 mg to about 2 mg.
4 . The orally disintegrating tablet of claim 1 , wherein the therapeutically effective amount of glycopyrrolate is effective for treating sialorrhea.
5 . The orally disintegrating tablet of claim 1 , wherein said tablet disintegrates in about five minutes or less upon contact with saliva.
6 . The orally disintegrating tablet of claim 5 , wherein said tablet disintegrates in about three minutes or less upon contact with saliva.
7 . The orally disintegrating tablet of claim 6 , wherein said tablet disintegrates in about one minute or less upon contact with saliva.
8 . A method of treating sialorrhea in a patient, comprising:
identifying a patient demonstrating sialorrhea; and
administering an orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate to the patient,
thereby treating sialorrhea in the patient.
9 . The method of claim 8 , wherein the therapeutically effective amount of glycopyrrolate is from about 1 mg to about 10 mg.
10 . The method of claim 9 , wherein the therapeutically effective amount of glycopyrrolate is from about 1 mg to about 2 mg.
11 . The method of claim 9 , wherein the therapeutically effective amount of glycopyrrolate is administered from one to three times daily.
12 . The method of claim 8 , wherein the patient is older than three years.
13 . The method of claim 8 , wherein the patient suffers from a neurological dysfunction or disorder.
14 . The method of claim 13 , wherein the neurological dysfunction or disorder is Parkinson's Disease, stroke, cerebral palsy, amyotrophic lateral sclerosis, or mental retardation.
15 . The method of claim 8 , wherein the patient suffers from facial paralysis or cancer about the face, neck, or esophagus.
16 . A method of treating sialorrhea in a patient, comprising the steps of:
providing to the patient or a caregiver of the patient a kit comprising one or more orally disintegrating tablets comprising a therapeutically effective amount of glycopyrrolate, prescribing information, and a container; and
instructing the patient or the caregiver of the patient regarding administering the orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate,
thereby treating sialorrhea in the patient.
17 . The method of claim 16 , wherein the therapeutically effective amount of glycopyrrolate is about 1 mg to about 10 mg.
18 . The method of claim 17 , wherein the therapeutically effective amount of glycopyrrolate is about 1 mg to about 2 mg.
19 . The method of claim 17 , wherein the therapeutically effective amount of glycopyrrolate is administered from one to three times daily.
20 . The method of claim 16 , wherein the patient is older than three years.
21 . The method of claim 16 , wherein the patient suffers from a neurological dysfunction or disorder.
22 . The method of claim 21 , wherein the neurological dysfunction or disorder is Parkinson's Disease, stroke, cerebral palsy, amyotrophic lateral sclerosis, or mental retardation.
23 . The method of claim 16 , wherein the patient suffers from facial paralysis or cancer about the face, neck, or esophagus.